Jade Biosciences develops antibody medicines for autoimmune diseases, starting with a candidate for the kidney disease IgA nephropathy. JBIO reports earnings on Thu, Nov 12, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 11 | Wedbush | Target raised | Buy | |
| Aug 11 | BTIG | Target raised | Buy | |
| Jun 15 | UBS | Initiated | Buy | |
| Jun 2 | Wedbush | Maintained | Buy | |
| Jun 1 | BTIG | Maintained | Buy |
Seasonality
How JBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in JBIO in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JBIO is in one of them and how their past JBIO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered JBIO in an article yet. Here's the latest on the wider market.
About Jade Biosciences
Jade Biosciences is a biopharmaceutical company based in Waltham, Massachusetts, that is developing antibody medicines for people with autoimmune diseases. Its main candidate, JADE101, targets a signaling protein called APRIL and is being developed first for IgA nephropathy, a progressive kidney disease. The company is also developing JADE201, which targets the BAFF receptor on B cells, for several autoimmune disorders. Its products are still in clinical trials and are not yet sold to patients.
- Headquarters
- Waltham, MA